Icon

Axogen Inc Stock Analysis and Price Target COMMON STOCK | Medical Devices | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 6.48

+0.26 (+4.18)%

USD 0.27B

0.36M

USD 12.50(+92.90%)

N/A

Icon

AXGN

Axogen Inc (USD)
COMMON STOCK | NSD
USD 6.48
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.27B

N/A

USD 6.48

Axogen Inc Stock Forecast

Show ratings and price targets of :
USD 12.50
(+92.90%)

Based on the Axogen Inc stock forecast from 3 analysts, the average analyst target price for Axogen Inc is USD 12.50 over the next 12 months. Axogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axogen Inc is Bearish, which is based on 1 positive signals and 9 negative signals. At the last closing, Axogen Inc’s stock price was USD 6.48. Axogen Inc’s stock price has changed by +9.83% over the past week, +73.73% over the past month and -38.17% over the last year.

No recent analyst target price found for Axogen Inc
No recent average analyst rating found for Axogen Inc

Company Overview Axogen Inc

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peri...Read More

https://www.axogeninc.com

13631 Progress Boulevard, Alachua, FL, United States, 32615

394

December

USD

USA

Adjusted Closing Price for Axogen Inc (AXGN)

Loading...

Unadjusted Closing Price for Axogen Inc (AXGN)

Loading...

Share Trading Volume for Axogen Inc Shares

Loading...

Compare Performance of Axogen Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AXGN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Axogen Inc (Sector: Medical Devices )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABL
Abacus Life Inc. -0.04 (-0.56%) USD161.99B 34.62 16.85

ETFs Containing AXGN

Symbol Name AXGN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Axogen Inc (AXGN) Stock

Based on ratings from 3 analysts Axogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.

AXGN stock's dividend yield is 2.61%. Our analysis grades AXGN stock's dividend yield at C-. This means that AXGN stock's dividend yield is above 70% of the stocks in the Medical Devices sector in the NSD exchange. Based on this AXGN may be a average dividend stock for its sector.

Based on targets from 3 analysts, the average taret price for AXGN is USD 12.50 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 9.

Unfortunately we do not have enough data on AXGN's stock to indicate if its overvalued.

The last closing price of AXGN's stock was USD 6.48.

The most recent market capitalization for AXGN is USD 0.27B.

Based on targets from 3 analysts, the average taret price for AXGN is projected at USD 12.50 over the next 12 months. This means that AXGN's stock price may go up by +92.90% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...